Immunotherapy in Head and Neck Squamous Cell Cancer

키워드

참고문헌 (48)

1. Bernier J, "Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer", N Engl J Med, 350(19), pp.1945~1952 (2004)
2. Cooper JS, "Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck", N Engl J Med, 350(19), pp.1937~1944 (2004)
3. Merlano M, "Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy", N Engl J Med, 327(16), pp.1115~1121 (1992)
4. Adelstein DJ, "An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer", J Clin Oncol, 21(1), pp.92~98 (2013)
5. al-Sarraf M, "Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study", J Clin Oncol, 15(1), pp.277~284 (1997)
6. Bonner JA, "Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival", Lancet Oncol, 11(1), pp.21~28 (2010)
7. Vermorken JB, "Platinum-based chemotherapy plus cetuximab in head and neck cancer", N Engl J Med, 359(11), pp.1116~1127 (2008)
8. Siano M, "Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy", Oral Oncol, 69, pp.33~37 (2017)
9. Chow LQ, "Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and", or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort, 2016, pp.34(32), 3838~3845
10. Ferris RL, "Nivolumab for recurrent squamous-cell carcinoma of the head and neck", N Engl J Med, 375(19), pp.1856~1867 (2016)
11. Szturz P, "Immunotherapy in head and neck cancer: aiming at extreme precision", BMC Med, 15(1), pp.110~ (2017)
12. Segal NH, "Updated safety and efficacy of durvalumab (MEDI 4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort", Ann Oncol, 27(suppl 6), pp.949~ (2016)
13. Seiwert TY, "Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial", Lancet Oncol, 17(7), pp.956~965 (2016)
14. Cohen EE, "Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R", M HNSCC): phase 3 KEYNOTE-040 trial, 2017, pp.28(Suppl 5), v605~v649
15. Machiels JP, "Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial", Lancet Oncol, 16(5), pp.583~594 (2015)
16. Blank CU, "Cancer immunology: the “cancer immunogram”", Science, 352(6286), pp.658~660 (2016)
17. Davis RJ, "Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer", Oral Oncol, 58, pp.59~70 (2016)
18. Lin DC, "The genomic landscape of nasopharyngeal carcinoma", Nat Genet, 46(8), pp.866~871 (2014)
19. Seiwert TY, "Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas", Clin Cancer Res, 21(3), pp.632~641 (2015)
20. Barber GN, "STING: infection, inflammation and cancer", Nat Rev Immunol, 15(12), pp.760~770 (2015)
21. Li K, "Promising targets for cancer immunotherapy: TLRs, RLRs, and STING-mediated innate immune pathways", Int J Mol Sci, 18(2), pp.E404~ (2017)
22. Wolchok JD, "Overall survival with combined nivolumab and ipilimumab in advanced melanoma", N Engl J Med, 377(14), pp.1345~1356 (2017)
23. Burugu S, "Emerging targets in cancer immunotherapy", Semin Cancer Biol, 52(Pt 2), pp.39~52 (2018)
24. Economopoulou P, "The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches", ESMO Open, 1(6), pp.e000122~ (2017)
25. Cohen EE, "Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)", J Clin Oncol, 32(15 suppl), pp.TPS3123~ (2014)
26. Chow LQ, "Phase Ib trial of the toll-like receptor 8 agonist, motolimod (VTX-2337), combined with cetuximab in patients with recurrent or metastatic SCCHN", Clin Cancer Res, 23(10), pp.2442~2450 (2017)
27. Kershaw MH, "Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment", Oncoimmunology, 2(9), pp.e25962~ (2013)
28. Vanpouille-Box C, "Toward precision radiotherapy for use with immune checkpoint blockers", Clin Cancer Res, 24(2), pp.259~265 (2018)
29. "Radiation therapy with durvalumab or cetuximab in treating patients with stage III-IVB head and neck cancer who cannot take cisplatin: NCT03258554" (2018)[URL]
30. "Cetuximab & Nivolumab in patients with recurrent/metastatic head & neck squamous cell carcinoma: NCT03370276" (2018)[URL]
31. "Pembrolizumab combined with cetuximab for treatment of recurrent/metastatic head & neck squamous cell carcinoma: NCT03082534" (2018)[URL]
32. "Phase Ib study of neoadjuvant of cetuximab plus motolimod and cetuximab plus motolimod plus nivolumab: NCT02124850" (2018)[URL]
33. "Pembrolizumab in combination with CRT for LA-SCCHN: NCT02586207" (2018)[URL]
34. "Immunotherapy with MK-3475 in surgically resectable head and neck squamous cell carcinoma: NCT02296684" (2018)[URL]
35. Smola S, "Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy", Ther Adv Vaccines, 5(3), pp.69~82 (2017)
36. Ooft ML, "Prognostic role of tumour-associated macrophages and regulatory T cells in EBV-positive and EBV-negative nasopharyngeal carcinoma", J Clin Pathol, 71(3), pp.267~274 (2018)
37. Bauml J, "Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study", J Clin Oncol, 35(14), pp.1542~1549 (2017)
38. Harrington KJ, "Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial", Lancet Oncol, 18(8), pp.1104~1115 (2017)
39. Mandal S, "The head and neck cancer immune landscape and its immunotherapeutic implications", JCI Insight, 1(17), pp.e89829~ (2016)
40. Saada-Bouzid E, "Hyperprogression during anti-PD-1", PD-L1 therapy in patients with recurrent and, Ann Oncol, pp.2017, 28(7)[DOI]
41. Haddad R, "Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R", M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: a biomarker analysis and updated clinical outcomes, 2017, pp.28(suppl 5), ~
42. Zhao M, "Negative immune factors might predominate local tumor immune status and promote carcinogenesis in cervical carcinoma", Virol J, 14(1), pp.5~ (2017)
43. Huang TT, "Alteration of SHP-1", p-STAT3 signaling: a potential target for anticancer therapy, 2017, pp.18(6), 1234~
44. Concha-Benavente F, "Reversing EGFR mediated immunoescape by targeted monoclonal antibody therapy", Front Pharmacol, 8, pp.332~ (2017)
45. Li CW, "Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity", Nat Commun, 7, pp.12632~ (2016)
46. Mattox AK, "PD-1 expression in head and neck squamous cell carcinomas derives primarily from functionally anergic CD4(+) TILs in the presence of PD-L1(+) TAMs", Cancer Res, 77(22), pp.6365~6374 (2017)
47. Muller T, "PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma", Oncotarget, 8(32), pp.52889~52900 (2017)
48. Yearley JH, "PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer", Clin Cancer Res, 23(12), pp.3158~3167 (2017)

관련 논문AI추천